- Home
- PBA vs ILMN Comparison
PBA vs ILMN Comparison
Compare PBA & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBA
- ILMN
- Stock Information
- Founded
- PBA 1997
- ILMN 1998
- Country
- PBA Canada
- ILMN United States
- Employees
- PBA N/A
- ILMN N/A
- Industry
- PBA Oil & Gas Production
- ILMN Medical Specialities
- Sector
- PBA Energy
- ILMN Health Care
- Exchange
- PBA Nasdaq
- ILMN Nasdaq
- Market Cap
- PBA 24.0B
- ILMN 22.9B
- IPO Year
- PBA N/A
- ILMN 2000
- Fundamental
- Price
- PBA $40.14
- ILMN $141.28
- Analyst Decision
- PBA Buy
- ILMN Buy
- Analyst Count
- PBA 1
- ILMN 20
- Target Price
- PBA $57.00
- ILMN $160.68
- AVG Volume (30 Days)
- PBA 1.1M
- ILMN 2.4M
- Earning Date
- PBA 11-05-2024
- ILMN 11-04-2024
- Dividend Yield
- PBA 5.05%
- ILMN N/A
- EPS Growth
- PBA 51.43
- ILMN N/A
- EPS
- PBA 2.43
- ILMN N/A
- Revenue
- PBA $7,305,229,650.00
- ILMN $4,390,000,000.00
- Revenue This Year
- PBA N/A
- ILMN N/A
- Revenue Next Year
- PBA $15.54
- ILMN $4.28
- P/E Ratio
- PBA $16.58
- ILMN N/A
- Revenue Growth
- PBA 37.18
- ILMN N/A
- 52 Week Low
- PBA $32.39
- ILMN $97.36
- 52 Week High
- PBA $43.44
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- PBA 34.09
- ILMN 51.78
- Support Level
- PBA $40.86
- ILMN $140.55
- Resistance Level
- PBA $41.54
- ILMN $145.37
- Average True Range (ATR)
- PBA 0.69
- ILMN 4.54
- MACD
- PBA -0.22
- ILMN 0.32
- Stochastic Oscillator
- PBA 1.27
- ILMN 77.29
About PBA Pembina Pipeline Corp. (Canada)
Pembina Pipeline is a midstream company serving the Canadian and North American (primarily Bakken) markets with an integrated product portfolio. Its assets include pipelines and gas gathering as well as assets across fractionation, storage, and propane exports.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.